Novo Nordisk files FDA application for once-weekly obesity drug CagriSema
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
India plays a critical role in Bristol Myers Squibb’s global strategy
The company operates a chain of mid-sized multi-speciality hospitals
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
This launch is part of the company's strategy to expand its nutraceutical portfolio
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
Subscribe To Our Newsletter & Stay Updated